Damora Therapeutics, Inc.
DMRA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for DMRA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DMRA
Damora Therapeutics, Inc. (DMRA) is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic diseases, with lead candidates GB0139, GB2064, and GB1211 in Phase 2 trials, and a recent strategic realignment toward GB3226 and GB1211.
Key risk: No approved products or revenue
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates for Damora Therapeutics, Inc..
Damora Therapeutics, Inc. (DMRA) is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic diseases, with lead candidates GB0139, GB2064, and GB1211 in Phase 2 trials, and a recent strategic realignment toward GB3226 and GB1211.
- Lead product candidate GB0139 is in Phase 2b clinical development for idiopathic pulmonary fibrosis (IPF) [sec · filed 2022-04-29].
- GB2064 is in a Phase 2a trial for myelofibrosis, and GB1211 is in a Phase 1b/2a trial for liver cirrhosis [sec · filed 2021-11-04].
- As of June 30, 2026, the company reported cash and equivalents of $540.5M, net income of -$31.2M, and shareholders' equity of $240.4M [sec].
- The company has a history of operating losses, with a net loss of $16.9M for the three months ended March 31, 2022 [sec · filed 2022-04-29].
- A strategic realignment has shifted focus to GB3226 and GB1211, with future funding needs dependent on multiple factors including trial progress and ability to raise capital [sec_mda · as of 2025-11-06].
What works
- The company has a substantial cash position of $540.5M as of June 30, 2026, providing a multi-year runway to advance its pipeline [sec].
- Multiple product candidates (GB0139, GB2064, GB1211) are in Phase 2 clinical trials, targeting large fibrotic disease markets such as IPF, myelofibrosis, and liver cirrhosis [sec · filed 2021-11-04].
- The strategic realignment to focus on GB3226 and GB1211 may allow more efficient allocation of resources toward promising candidates [sec_mda · as of 2025-11-06].
What to weigh
- The company has a history of significant operating losses and negative cash flows, with net losses of $16.9M for Q1 2022 and continued negative cash flows expected for the foreseeable future [sec · filed 2022-04-29].
- All product candidates are in early-to-mid stage clinical development, and the company has no approved products or revenue from product sales [sec · filed 2022-04-29].
- Future funding requirements are uncertain and depend on numerous factors including clinical trial outcomes, regulatory approvals, and the ability to raise additional capital [sec_mda · as of 2025-11-06].
- The company may need to delay, reduce, or terminate planned activities if sufficient funding is not obtained [sec · filed 2022-04-29].
From the filings
Quoted directly from source documents.
GB0139 is the most advanced product candidate, in Phase 2b clinical development for IPF.
“Our most advanced product candidate, GB0139, is in Phase 2b clinical development”
SEC filings · April 29, 2022
The company had a net loss of $16.9 million for the three months ended March 31, 2022.
“Net loss was $16.9 million and $13.3 million for the three months ended March 31, 2022 and 2021, respectively.”
SEC filings · April 29, 2022
The company has strategically realigned its focus to GB3226 and GB1211.
“our new focus on GB3226 and GB1211 and our ability to execute successfully on our strategic realignment and realigned focus”
SEC MD&A · November 6, 2025
The company's cash position as of June 30, 2021 was $137.7 million, expected to fund operations into the second half of 2024.
“existing cash, cash equivalents and marketable securities of $137.7 million as of June 30, 2021 will be sufficient to fund our operating expenditures and capital expenditure requirements into the second half of 2024.”
SEC filings · August 5, 2021
Risks & what to watch (4)›
Key risks
- No approved products or revenue — All candidates are in clinical or preclinical stages; no product revenue has been generated [sec · filed 2022-04-29].
- History of operating losses — Net loss of $16.9M in Q1 2022 and negative cash flows expected to continue [sec · filed 2022-04-29].
- Uncertain future funding needs — Capital requirements depend on trial progress, regulatory outcomes, and ability to raise funds [sec_mda · as of 2025-11-06].
- Clinical development risks — Phase 2 trials may fail; delays or negative results could halt programs [sec · filed 2023-04-28].
What to watch
- Clinical data readouts from ongoing Phase 2 trials of GB0139 (IPF), GB2064 (myelofibrosis), and GB1211 (liver cirrhosis) [sec · filed 2021-11-04].
- Progress of the strategic realignment toward GB3226 and GB1211 and any updates on pipeline prioritization [sec_mda · as of 2025-11-06].
- Cash runway updates: as of June 30, 2026, cash was $540.5M; future spending rates and any capital raises will be key [sec].
- Regulatory interactions or milestones for any product candidate, including potential FDA or EMA feedback [sec · filed 2022-04-29].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Damora Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Damora Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
74.3 months
D/E 0.05 · 0% dilution
Lead: Phase 2
6 candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
60
Total value held
$959.8M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 9,045,481 | $234.3M |
| perceptive advisors llc | 2,446,000 | $63.4M |
| fcpm iii services b.v. | 2,441,000 | $63.2M |
| ra capital management, l.p. | 2,399,310 | $62.1M |
| janus henderson group plc | 2,362,696 | $61.4M |
| viking global investors lp | 2,311,082 | $59.9M |
| commodore capital lp | 1,939,000 | $50.2M |
| cormorant asset management, lp | 1,525,000 | $39.5M |
| balyasny asset management l.p. | 1,448,000 | $37.5M |
| a16z capital management, l.l.c. | 1,236,157 | $32.0M |
Showing top 10 of 60 institutional holders of Damora Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 1.4%
- Days to cover
- 3.0
- Shares short
- 827,221
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DMRA short interestFrequently asked questions
What is the AI investment thesis for Damora Therapeutics, Inc.?
Damora Therapeutics, Inc. (DMRA) is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic diseases, with lead candidates GB0139, GB2064, and GB1211 in Phase 2 trials, and a recent strategic realignment toward GB3226 and GB1211.
What is Damora Therapeutics, Inc.'s lead drug candidate?
Damora Therapeutics, Inc.'s most advanced tracked candidate is dmr-001 (Preclinical) for Essential thrombocythemia (ET) and myelofibrosis (MF).
Who is the CEO of Damora Therapeutics, Inc.?
Ms. Jennifer A. Jarrett M.B.A. is the chief executive officer of Damora Therapeutics, Inc. (DMRA).
Where is Damora Therapeutics, Inc. headquartered?
Damora Therapeutics, Inc. (DMRA) is headquartered in Waltham, MA, United States.
What therapeutic areas does Damora Therapeutics, Inc. focus on?
Damora Therapeutics, Inc. develops therapies across Oncology, Hematology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.